GlaxoSmithKline To Shutter Second Largest Drug Factory In Romania, 236 Jobs Gone
Glaxo is axing jobs but others are hiring too! Check it out! (Isn't it tempting?)
Factory In Brasov Out Of GSK's Global Network Of Production By The End Of 2015
In June 2013, GSK announced its decision that the plant in Brasov to leave the network to global production for solid oral forms. Since the initial announcement, GSK carefully explored the opportunity to sell the plant to a third party with a transitional agreement production.
In the last 10 months, GSK has gone through a rigorous process of sale to ensure that it was done a complete search of potential buyers and that every opportunity has been carefully reviewed for both factory cat and employees. Since Unfortunately, GSK was not in a position to agree on a viable solution to any of the interested parties so as to be secured places work for as many of the employees, for as long as possible, while at the same time, GSK's business sense.
GSK will treat employees fairly, with respect and integrity and will provide adequate support.
Severance packages, support in finding a new place of work, counseling and other forms of assistance will be provided.
Unfortunately, the closure of the factory in Brasov. It is anticipated that the closure will be completed by the end of 2015, following a rigorous process of sale which took place in the last 10 months. Meanwhile, we have ensured that conduct a thorough search of potential buyers and that every opportunity was reviewed very carefully, both to employers and to the factory. Since Unfortunately, GSK is in a position to agree on a viable solution to any of the interested parties.
In June 2013, GSK announced its decision to plant in Brasov to emerge from our global network of manufacturing the solid oral forms. This decision was due to the overcapacity of production in the current network of solid oral doses of GSK. The capacity production plant in Brasov is underutilized and there exists potential growth in the long term as alteproduse or volumes to be made ??here, due to technological limitations and equipment. Since the initial announcement, GSK carefully explored opportunities to sell the factory in Brasov by a third party, an agreement transient production.
There have been a number of criteria on which GSK has conducted the analysis, a key criterion being that GSK was seeking a buyer who places provide work for as many of the factory employees for as long as possible, having in Meanwhile, a GSK's business sense. To achieve this, discussions have been held around the transitional agreement production.
GSK has worked with interested companies and conducted in-depth analysis to understand more about the companies concerned and their specific plans for the long term future of the plant. Unfortunately, GSK was in a position to agree on a viable solution to any of the interested parties. Commenting on the decision, Mariana Cismaru, Brasov plant manager, said: "It was a complex process and it was important to consider all factors to take a careful and well-founded decision. Employees of Brasov have made ??a significant contribution to the success of GSK over the years, and this decision does not reflect in any way the team performance of Brasov. "
GSK sincerely regret the impact that this decision has on people through job loss job. GSK will do everything you can to help factory employees to go through this difficult time. As always, we will treat employees fairly, with respect and integrity and we will provide the necessary support. Severance packages, support in finding a new place of work, counseling and other assistance will be also offered factory workers.
"GSK remains committed to the local market. We are already in Romania 25 years and will continue to be one of the most important employers in the local market, with a total of over 600 employees in our business pharmaceuticals, consumer healthcare and distribution. Meanwhile, by 2018, we will invest between 8 and 10 million in research and development and, as we have done in all these years, we continue to support local communities, "said Barbara Cygler, General Manager GSK Romania.
Currently, 236 people work in the factory in Brasov. Production will continue this until all the products will be transferred to alternative sites of GSK, in Poland and Spain. Brasov factory was founded in 1994 and produces a wide range of drugs including Seroxat - depression, Retrovir - to treat HIV / AIDS, Duact and Sucrets - for respiratory diseases, and products for maintaining the health, Panadol, Coldrex, Parasinus and Marcofen.
For questions, please contact the Adelina Nedelcu (adelina.e.nedelcu @ gsk.com, 0732 307 274)
GSK - one of the largest pharmaceutical companies in the world, whose portfolio is based on a substantial activity of research and development. GSK is committed to improving people's lives, helping them to achieve more, to be feel better and live longer. For more information, see www.gsk.ro and www.gsk.com.
Help employers find you! Check out all the jobs and post your resume.
Factory In Brasov Out Of GSK's Global Network Of Production By The End Of 2015
In June 2013, GSK announced its decision that the plant in Brasov to leave the network to global production for solid oral forms. Since the initial announcement, GSK carefully explored the opportunity to sell the plant to a third party with a transitional agreement production.
In the last 10 months, GSK has gone through a rigorous process of sale to ensure that it was done a complete search of potential buyers and that every opportunity has been carefully reviewed for both factory cat and employees. Since Unfortunately, GSK was not in a position to agree on a viable solution to any of the interested parties so as to be secured places work for as many of the employees, for as long as possible, while at the same time, GSK's business sense.
GSK will treat employees fairly, with respect and integrity and will provide adequate support.
Severance packages, support in finding a new place of work, counseling and other forms of assistance will be provided.
Unfortunately, the closure of the factory in Brasov. It is anticipated that the closure will be completed by the end of 2015, following a rigorous process of sale which took place in the last 10 months. Meanwhile, we have ensured that conduct a thorough search of potential buyers and that every opportunity was reviewed very carefully, both to employers and to the factory. Since Unfortunately, GSK is in a position to agree on a viable solution to any of the interested parties.
In June 2013, GSK announced its decision to plant in Brasov to emerge from our global network of manufacturing the solid oral forms. This decision was due to the overcapacity of production in the current network of solid oral doses of GSK. The capacity production plant in Brasov is underutilized and there exists potential growth in the long term as alteproduse or volumes to be made ??here, due to technological limitations and equipment. Since the initial announcement, GSK carefully explored opportunities to sell the factory in Brasov by a third party, an agreement transient production.
There have been a number of criteria on which GSK has conducted the analysis, a key criterion being that GSK was seeking a buyer who places provide work for as many of the factory employees for as long as possible, having in Meanwhile, a GSK's business sense. To achieve this, discussions have been held around the transitional agreement production.
GSK has worked with interested companies and conducted in-depth analysis to understand more about the companies concerned and their specific plans for the long term future of the plant. Unfortunately, GSK was in a position to agree on a viable solution to any of the interested parties. Commenting on the decision, Mariana Cismaru, Brasov plant manager, said: "It was a complex process and it was important to consider all factors to take a careful and well-founded decision. Employees of Brasov have made ??a significant contribution to the success of GSK over the years, and this decision does not reflect in any way the team performance of Brasov. "
GSK sincerely regret the impact that this decision has on people through job loss job. GSK will do everything you can to help factory employees to go through this difficult time. As always, we will treat employees fairly, with respect and integrity and we will provide the necessary support. Severance packages, support in finding a new place of work, counseling and other assistance will be also offered factory workers.
"GSK remains committed to the local market. We are already in Romania 25 years and will continue to be one of the most important employers in the local market, with a total of over 600 employees in our business pharmaceuticals, consumer healthcare and distribution. Meanwhile, by 2018, we will invest between 8 and 10 million in research and development and, as we have done in all these years, we continue to support local communities, "said Barbara Cygler, General Manager GSK Romania.
Currently, 236 people work in the factory in Brasov. Production will continue this until all the products will be transferred to alternative sites of GSK, in Poland and Spain. Brasov factory was founded in 1994 and produces a wide range of drugs including Seroxat - depression, Retrovir - to treat HIV / AIDS, Duact and Sucrets - for respiratory diseases, and products for maintaining the health, Panadol, Coldrex, Parasinus and Marcofen.
For questions, please contact the Adelina Nedelcu (adelina.e.nedelcu @ gsk.com, 0732 307 274)
GSK - one of the largest pharmaceutical companies in the world, whose portfolio is based on a substantial activity of research and development. GSK is committed to improving people's lives, helping them to achieve more, to be feel better and live longer. For more information, see www.gsk.ro and www.gsk.com.
Help employers find you! Check out all the jobs and post your resume.